This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Arecor continues to progress a robust portfolio of revenue-generating partnered programmes underscoring the strength of our Arestat™ technology, its value to partner companies and its ability to provide near-term revenue generation and long-term value for shareholders.
Partnership portfolio highlights
- Arestat™-enhanced biosimilar product, AT220, generating growing royalties under a worldwide licensing agreement
- Sanofi continues to actively progress potential pivotal registrational study for SAR447537, formerly INBRX-101 (AT292), acquired from Inhibrx, which incorporates Arestat™ technology and is under a revenue-generating license with Sanofi
- Exclusive milestone and royalty-bearing licensing agreement with a wholly owned subsidiary of one of the world’s largest independent chemicals marketing companies, granting rights to Arestat™-enhanced AT351
- Growing portfolio of pre-license technology partnerships, offering upside potential from partnering
How we work with partners
Arecor has a strong reputation as a reliable and collaborative partner. We work with like-minded companies to ensure that our partnerships align with partners’ interests to maximise the chances of success.
We work in collaboration with companies under a technology licensing model with the aim of developing enhanced versions of their developmental and commercial high-value complex biological products.
These collaborations typically start with identification of a differentiated product opportunity and then a formulation development study, where Arecor applies Arestat™ to develop a novel formulation of the partner’s medicine to achieve a superior target product profile.
Such collaborations are revenue generating from day one through technology development fees. Upon completion, the partner has the option to enter into a license agreement for rights to access the intellectual property and further develop and commercialise the novel formulation. These licenses typically involve both milestone and royalty payments and represent significant future recurring revenue upside potential.
Applying our Arestat™ technology
Arecor targets its technology partnering programmes at high-value biologics, including biosimilars, novel biologics, peptides and vaccines, as well as future potential applications such as oral delivery, mRNA and cell and gene therapies.
The products can be at any stage in development from early phase clinical development through to products that are already on the market. The most likely candidates are complex specialty products used for the treatment of chronic or life-threatening diseases with a high cost, requiring special storage, handling or complex administration where Arecor can leverage the Arestat™ technology to improve and differentiate these characteristics.